Isoform-Selective Activation of Protein Kinase C by Nitric Oxide in the Heart of Conscious Rabbits: A Signaling Mechanism for Both Nitric Oxide–Induced and Ischemia-Induced Preconditioning
The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
Abstract —Although isoform-selective translocation of protein kinase C (PKC) ε appears to play an important role in the late phase of ischemic preconditioning (PC), the mechanism(s) responsible for such translocation remains unclear. Furthermore, the signaling pathway that leads to the development of late PC after exogenous administration of NO in the absence of ischemia (NO donor–induced late PC) is unknown. In the present study we tested the hypothesis that NO activates PKC and that this is the mechanism for the development of both ischemia-induced and NO donor–induced late PC. A total of 95 chronically instrumented, conscious rabbits were used. In rabbits subjected to ischemic PC (six 4-minute occlusion/4-minute reperfusion cycles), administration of the NO synthase inhibitor N ω -nitro- l -arginine (group III), at doses previously shown to block the development of late PC, completely blocked the ischemic PC–induced translocation of PKCε but not of PKCη, indicating that increased formation of NO is an essential mechanism whereby brief ischemia activates the ε isoform of PKC. Conversely, a translocation of PKCε and -η quantitatively similar to that induced by ischemic PC could be reproduced pharmacologically with the administration of 2 structurally unrelated NO donors, diethylenetriamine/NO (DETA/NO) and S -nitroso- N -acetylpenicillamine (SNAP), at doses previously shown to elicit a late PC effect. The particulate fraction of PKCε increased from 35±2% of total in the control group (group I) to 60±1% after ischemic PC (group II) ( P <0.05), to 54±2% after SNAP (group IV) ( P <0.05) and to 52±2% after DETA/NO (group V) ( P <0.05). The particulate fraction of PKCη rose from 66±5% in the control group to 86±3% after ischemic PC ( P <0.05), to 88±2% after SNAP ( P <0.05) and to 85±1% after DETA/NO ( P <0.05). Neither ischemic PC nor NO donors had any appreciable effect on the subcellular distribution of PKCα, -β1, -β2, -γ, -δ, -μ, or -ι/λ; on total PKC activity; or on the subcellular distribution of total PKC activity. Thus, the effects of SNAP and DETA/NO on PKC closely resembled those of ischemic PC. The DETA/NO–induced translocation of PKCε (but not that of PKCη) was completely prevented by the administration of the PKC inhibitor chelerythrine at a dose of 5 mg/kg (group VI) (particulate fraction of PKCε, 38±4% of total, P <0.05 versus group V; particulate fraction of PKCη, 79±2% of total). The same dose of chelerythrine completely prevented the DETA/NO–induced late PC effect against both myocardial stunning (groups VII through X) and myocardial infarction (groups XI through XV), indicating that NO donors induce late PC by activating PKC and that among the 10 isozymes of PKC expressed in the rabbit heart, the ε isotype is specifically involved in the development of this form of pharmacological PC. In all groups examined (groups I through VI), the changes in the subcellular distribution of PKCε protein were associated with parallel changes in PKCε isoform–selective activity, whereas total PKC activity was not significantly altered. Taken together, the results provide direct evidence that isoform-selective activation of PKCε is a critical step in the signaling pathway whereby NO initiates the development of a late PC effect both after an ischemic stimulus (endogenous NO) and after treatment with NO-releasing agents (exogenous NO). To our knowledge, this is also the first report that NO can activate PKC in the heart. The finding that NO can promote isoform-specific activation of PKC identifies a new biological function of this radical and a new mechanism in the signaling cascade of ischemic PC and may also have important implications for other pathophysiological conditions in which NO is involved and for nitrate therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Beckman, J. S., Beckman, T. W., Chen, J., Marshall, P. A., & Freeman, B. A. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.4.1620 · Cited by 7,029
Some statistical methods useful in circulation research.
Wallenstein, S., Zucker, C. L., & Fleiss, J. L. (1980) · Circulation Research · doi:10.1161/01.res.47.1.1 · Cited by 3,886
Chelerythrine is a potent and specific inhibitor of protein kinase C
Herbert, J. M., Augereau, J. M., Gleye, J., & Maffrand, J. P. (1990) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(90)91544-3 · Cited by 1,195
Marber, M. S., Latchman, D. S., Walker, J. M., & Yellon, D. M. (1993) · Circulation · doi:10.1161/01.cir.88.3.1264 · Cited by 1,001
Nitric Oxide: Pathophysiological Mechanisms
Gross, S. S., & Wolin, M. S. (1995) · Annual Review of Physiology · doi:10.1146/annurev.ph.57.030195.003513 · Cited by 888
Mitochondrial ATP-Dependent Potassium Channels: Novel Effectors of Cardioprotection?
Liu, Y., Sato, T., O’Rourke, B., & Marban, E. (1998) · Circulation · doi:10.1161/01.cir.97.24.2463 · Cited by 816
Maragos, C. M., Morley, D., Wink, D. A., Dunams, T. M., Saavedra, J. E., Hoffman, A., Bove, A. A., Isaac, L., Hrabie, J. A., & Keefer, L. K. (1991) · Journal of Medicinal Chemistry · doi:10.1021/jm00115a013 · Cited by 722
Xia, Y., Dawson, V. L., Dawson, T. M., Snyder, S. H., & Zweier, J. L. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.13.6770 · Cited by 718
Nitric Oxide and Cardiac Function
Kelly, R. A., Balligand, J.-L., & Smith, T. W. (1996) · Circulation Research · doi:10.1161/01.res.79.3.363 · Cited by 711
Delayed effects of sublethal ischemia on the acquisition of tolerance to ischemia.
Kuzuya, T., Hoshida, S., Yamashita, N., Fuji, H., Oe, H., Hori, M., Kamada, T., & Tada, M. (1993) · Circulation Research · doi:10.1161/01.res.72.6.1293 · Cited by 628
Cited by
Mechanisms Underlying Acute Protection From Cardiac Ischemia-Reperfusion Injury
Murphy, E., & Steenbergen, C. (2008) · Physiological Reviews · doi:10.1152/physrev.00024.2007 · Cited by 1,465
Preconditioning the myocardium: from cellular physiology to clinical cardiology
YELLON, D. M., & DOWNEY, J. M. (2003) · Physiological Reviews · doi:10.1152/physrev.00009.2003 · Cited by 1,062
“This PKC activation was seen to be NO dependent and could be blocked by pretreatment with the nonselective NOS inhibitor L-NA (271).”
BackgroundThe Late Phase of Preconditioning
Bolli, R. (2000) · Circulation Research · doi:10.1161/01.res.87.11.972 · Cited by 757
Self-citationConsequences of Brief Ischemia: Stunning, Preconditioning, and Their Clinical Implications: Part 1
Kloner, R. A., & Jennings, R. B. (2001) · Circulation · doi:10.1161/hc4801.100038 · Cited by 634
Bolli, R. (2001) · Journal of Molecular and Cellular Cardiology · doi:10.1006/jmcc.2001.1462 · Cited by 595
Self-citationSurvival kinases in ischemic preconditioning and postconditioning
HAUSENLOY, D., & YELLON, D. (2006) · Cardiovascular Research · doi:10.1016/j.cardiores.2006.01.017 · Cited by 472
Pharmacology of cardiac potassium channels
Tamargo, J. (2004) · Cardiovascular Research · doi:10.1016/j.cardiores.2003.12.026 · Cited by 466
Baines, C. P., Song, C.-X., Zheng, Y.-T., Wang, G.-W., Zhang, J., Wang, O.-L., Guo, Y., Bolli, R., Cardwell, E. M., & Ping, P. (2003) · Circulation Research · doi:10.1161/01.res.0000069215.36389.8d · Cited by 450
Self-citationBaines, C. P., Zhang, J., Wang, G.-W., Zheng, Y.-T., Xiu, J. X., Cardwell, E. M., Bolli, R., & Ping, P. (2002) · Circulation Research · doi:10.1161/01.res.0000012702.90501.8d · Cited by 429
Self-citationShinmura, K., Tang, X.-L., Wang, Y., Xuan, Y.-T., Liu, S.-Q., Takano, H., Bhatnagar, A., & Bolli, R. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.18.10197 · Cited by 381
Self-citationIschemic Preconditioning Activates Phosphatidylinositol-3-Kinase Upstream of Protein Kinase C
Tong, H., Chen, W., Steenbergen, C., & Murphy, E. (2000) · Circulation Research · doi:10.1161/01.res.87.4.309 · Cited by 365
Biology of nitric oxide signaling
Liaudet, L., Soriano, F. G., & Szabó, C. (2000) · Critical Care Medicine · doi:10.1097/00003246-200004001-00005 · Cited by 326
KATP channels and myocardial preconditioning: an update
Gross, G. J., & Peart, J. N. (2003) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00421.2003 · Cited by 323
Gonzalez-Zulueta, M., Feldman, A. B., Klesse, L. J., Kalb, R. G., Dillman, J. F., Parada, L. F., Dawson, T. M., & Dawson, V. L. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.1.436 · Cited by 315
Xuan, Y.-T., Tang, X.-L., Banerjee, S., Takano, H., Li, R. C. X., Han, H., Qiu, Y., Li, J.-J., & Bolli, R. (1999) · Circulation Research · doi:10.1161/01.res.84.9.1095 · Cited by 300
Self-citationParacrine and autocrine effects of nitric oxide on myocardial function
Shah, A. (2000) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(99)00072-8 · Cited by 293
Hydrogen Sulfide in the Mammalian Cardiovascular System
Liu, Y.-H., Lu, M., Hu, L.-F., Wong, P. T.-H., Webb, G. D., & Bian, J.-S. (2012) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.4005 · Cited by 264
Cai, Z., Zhong, H., Bosch-Marce, M., Fox-Talbot, K., Wang, L., Wei, C., Trush, M. A., & Semenza, G. L. (2007) · Cardiovascular Research · doi:10.1093/cvr/cvm035 · Cited by 244
“AKT phosphorylates nitric oxide synthase and increases the production of nitric oxide, leading to PKC-1 activation.(24) Activated PKC-1 associates with the MPTP and inhibits its opening.”
BackgroundMurphy, E. (2004) · Circulation Research · doi:10.1161/01.res.0000108082.76667.f4 · Cited by 240
Münzel, T., Li, H., Mollnau, H., Hink, U., Matheis, E., Hartmann, M., Oelze, M., Skatchkov, M., Warnholtz, A., Duncker, L., et al. (2000) · Circulation Research · doi:10.1161/01.res.86.1.e7 · Cited by 234
ROS and NO trigger early preconditioning: relationship to mitochondrial KATP channel
Lebuffe, G., Schumacker, P. T., Shao, Z.-H., Anderson, T., Iwase, H., & Vanden Hoek, T. L. (2003) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00706.2002 · Cited by 227
“However, the requirement for RNS in the triggering of preconditioning is controversial, as some groups find evidence for the involvement of nitric oxide (NO) during the early window of protection (21, 32) but others”
BackgroundHANLEY, P., & DAUT, J. (2005) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2005.04.002 · Cited by 218
“In some recent studies, opening of mKATP channels has been inferred to be the initial trigger of the cardioprotective effect, promoting the generation of ROS and inducing the activation of PKCe [37,82,91,103], whereas Lebuffe et al. [109] proposed that generation of ROS during the trigger phase leads to the opening of…”
BackgroundInfluentialNakano, A., Liu, G. S., Heusch, G., Downey, J. M., & Cohen, M. V. (2000) · Journal of Molecular and Cellular Cardiology · doi:10.1006/jmcc.2000.1152 · Cited by 171
Is nitric oxide overproduction the target of choice for the management of septic shock?
Feihl, F., Waeber, B., & Liaudet, L. (2001) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(01)00155-3 · Cited by 151
Metadata
- Authors
- Ping, P., Takano, H., Zhang, J., Tang, X.-L., Qiu, Y., Li, R. C. X., Banerjee, S., Dawn, B., Balafonova, Z., & Bolli, R.
- Venue
- Circulation Research
- Published
- 1999-03-19
- Volume
- 84
- Issue
- 5
- Pages
- 587-604
- ISSN
- 0009-7330 (ISSN-L)
- 1524-4571
- OpenAlex
- W2134643192
- Cited by
- 257
- References
- 58
- FWCI
- 17.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.